Allos CEO resigns
Executive Summary
Allos Therapeutics CEO and CFO Michael Hart will resign his positions following appointment of a successor CEO. During Hart's tenure, Allos received an "approvable" letter for Efaproxyn (efaproxiral) for use as an adjunct to whole brain radiation therapy for the treatment of brain metastases from breast cancer (1"The Pink Sheet" June 7, 2004, p. 6). Hart joined Allos in 1999 as chief financial officer and senior VP-operations. He was promoted to president and CEO in December 2001, and appointed to the board of directors in April 2002...